Metformin may lower colorectal cancer risk by stopping precancerous lesion formation
the ONA take:
Metformin may lower colorectal cancer risk by reducing the formation of precancerous lesions, according to a study published online ahead of print in the journal Cancer Epidemiology, Biomarkers & Prevention.
Because previous research has suggested that metformin may lower colorectal cancer risk in patients with diabetes and most colorectal cancers originate in precancerous adenomas, researchers from Kaiser Permanente in California and the University of Pennsylvania Perelman School of Medicine sought to determine whether metformin use lowered colorectal adenoma risk following polypectomy in patients with type 2 diabetes.
Researchers retrospectively analyzed data from 2,142 patients age 40 to 89 years with type 2 diabetes, at least one adenoma at baseline colonoscopy, and at least one adenoma at repeat colonoscopy 1 to 10 years from baseline colonoscopy.
Results showed that metformin use was associated with lower adenoma recurrence risk. Researchers found that the association was stronger with increasing total metformin dose.
“Our study suggests a potential benefit of metformin use in lowering the risk of subsequent adenomas after polypectomy in patients with type 2 diabetes,” the authors conclude.
Metformin may lower colorectal cancer risk by reducing the formation of precancerous lesions.
Sign Up for Free e-newsletters
- Leukemia Risk in Children, Maternal Use of Hormonal Contraception Linked in Population Study
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Molecular Features May Predict Response in Primary Pancreatic Cancer
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Clinical Characteristics That Increase Risk of Chemotherapy-Induced Febrile Neutropenia Identified
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Counseling Patients on Oral Chemotherapy
- Patients and Caregivers Worry About Cost of Cancer Care
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|